Citations

Clear

4847 citation(s) found for "Tu, Eric".

Circulating Serum Free Light Chains As Predictive Markers of AIDS-Related Lymphoma
Goedert, James J. , Wilson, Wyndham H. , Dunleavy, Kieron , Kyle, Robert A. , Katzmann, Jerry A., Rajkumar, S. Vincent , Landgren, Ola , Rabkin, Charles S. , Engels, Eric A. , Rajkumar, S Vincent , Dunleavy, Kieron

Mayo Clinic

Journal of Clinical Oncology | January 4, 2010 | Volume: 28 | Issue: 5 | Pages: 773-779

10.1200/jco.2009.25.1322 | PMID 20048176 Get It

Purpose HIV-infected persons have an elevated risk of developing non-Hodgkin's lymphoma (NHL); this risk remains increased in the era of effective HIV therapy. We evaluated serum immunoglobulin (Ig) proteins as predictors of NHL risk among HIV-infected individuals. Patients and Methods By using three cohorts of HIV-infected persons (from 1982 to 2005), we identified 66 individuals who developed NHL and 225 matched (by cohort, sex, ethnicity, age, and CD4 count), HIV-infected, lymphoma-free controls who had available stored prediagnostic blood samples. Serum/plasma samples obtained 0 to 2 years and 2 to 5 years before diagnosis/selection were assayed for IgG, IgM, and IgA levels; monoclonal (M) Igs; and κ and λ free light chain (FLC) levels. Patients and matched controls were compared by using conditional logistic regression. Results The κ and λ FLCs were both significantly higher in patients (eg, in 2- to 5-year window: median κ, 4.24 v 3.43 mg/dL; median λ, 4.04 v 3.09 mg/dL) and strongly predicted NHL in a dose-response manner up to 2 to 5 years before diagnosis/selection (eg, NHL risk 3.76-fold higher with κ concentration at least 2.00 times the upper limit of normal, and 8.13-fold higher with λ concentration at least 2.00 times the upper limit of normal compared with normal levels). In contrast, IgG, IgM, and IgA levels were similar in patients and controls. M proteins were detected in only two patients with NHL (3%) and in nine controls (4%), and they were not significantly associated with NHL risk. Conclusion Elevated FLCs may represent sensitive markers of polyclonal B-cell activation and dysfunction and could be useful for identifying HIV-infected persons at increased NHL risk.
Functional Genetic Polymorphisms in the Aromatase Gene CYP19 Vary the Response of Breast Cancer Patients to Neoadjuvant Therapy with Aromatase Inhibitors
Wang, Liewei , Ellsworth, Katarzyna A. , Moon, Irene, Pelleymounter, Linda L., Eckloff, Bruce W., Martin, Yvette N. , Jenkins, Gregory D. , Batzler, Anthony , Ravi, Saranya , Dixon, J. Michael , Wieben, Eric D. , Buzdar, Aman U. , Weinshilboum, Richard M. , Fridley, Brooke L. , Suman, Vera J. , Miller, William R. , Weinshilboum, Richard M. , Ingle, James N.

Mayo Clinic

Cancer Research | January 4, 2010 | Volume: 70 | Issue: 1 | Pages: 319-328

10.1158/0008-5472.can-09-3224 | PMID 20048079 Get It

Abstract Aromatase (CYP19) is a critical enzyme in estrogen biosynthesis and aromatase inhibitors (AI) are employed widely for endocrine therapy in postmenopausal women with breast cancer. We hypothesized that single nucleotide polymorphisms (SNPs) in the CYP19 gene may alter the effectiveness of AI therapy in the neoadjuvant setting. Genomic DNA was obtained for sequencing from 52 women pre-AI and post-AI treatment in this setting. Additionally, genomic DNA obtained from 82 samples of breast cancer and 19 samples of normal breast tissue was subjected to resequencing. No differences in CYP19 sequence were observed between tumor and germ-line DNA in the same patient. A total of 48 SNPs were identified including 4 novel SNPs when compared with previous resequencing data. For genotype-phenotype association studies, we determined the levels of aromatase activity, estrone, estradiol, and tumor size in patients pre-AI and post-AI treatment. We defined two tightly linked SNPs (rs6493497 and rs7176005 in the 5'-flanking region of CYP19 exon 1.1) that were significantly associated with a greater change in aromatase activity after AI treatment. In a follow-up study of 200 women with early-stage breast cancer who were treated with adjuvant anastrozole, these same two SNPs were also associated with higher plasma estradiol levels in patients pre-AI and post-AI treatment. Electrophoretic mobility shift and reporter gene assays confirmed likely functional effects of these two SNPs on transcription of CYP19. Our findings indicate that two common genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to aromatase inhibitors. Cancer Res; 70(1); 319–28
Thyrotropin Secretion in Mild and Severe Primary Hypothyroidism Is Distinguished by Amplified Burst Mass and Basal Secretion with Increased Spikiness and Approximate Entropy
Roelfsema, Ferdinand , Pereira, Alberto M. , Adriaanse, Ria, Endert, Erik , Fliers, Eric , Romijn, Johannes A. , Veldhuis, Johannes D.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | December 5, 2009 | Volume: 95 | Issue: 2 | Pages: 928-934

10.1210/jc.2009-1959 | PMID 19965923 Get It

Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
Yao, James C. , Baudin, Éric , Kvols, Larry K., Rougier, Philippe, Ruszniewski, Philippe, Hoosen, Sakina, Peter, J., Haas, T , Lebwohl, David , Kulke, Matthew H. , Hobday, Timothy J. , O’Dorisio, Thomas M. , Shah, Manisha H. , Cadiot, Guillaume , Luppi, Gabriele , Posey, James , Wiedenmann, Bertram , Lombard‐Bohas, Catherine , Cutsem, Eric Van

Mayo Clinic

Journal of Clinical Oncology | November 23, 2009 | Volume: 28 | Issue: 1 | Pages: 69-76

10.1200/jco.2009.24.2669 | PMID 19933912 Get It

Purpose No established treatment exists for pancreatic neuroendocrine tumor (NET) progression after failure of chemotherapy. Everolimus (RAD001), an oral inhibitor of mammalian target of rapamycin, in combination with octreotide has demonstrated encouraging antitumor activity in patients with NETs. Patients and Methods This open-label, phase II study assessed the clinical activity of everolimus in patients with metastatic pancreatic NETs who experienced progression on or after chemotherapy. Patients were stratified by prior octreotide therapy (stratum 1: everolimus 10 mg/d, n = 115; stratum 2: everolimus 10 mg/d plus octreotide long-acting release [LAR], n = 45). Tumor assessments (using Response Evaluation Criteria in Solid Tumors) were performed every 3 months. Chromogranin A (CgA) and neuron-specific enolase (NSE) were assessed monthly if elevated at baseline. Trough concentrations of everolimus and octreotide were assessed. Results By central radiology review, in stratum 1, there were 11 partial responses (9.6%), 78 patients (67.8%) with stable disease (SD), and 16 patients (13.9%) with progressive disease; median progression-free survival (PFS) was 9.7 months. In stratum 2, there were two partial responses (4.4%), 36 patients (80%) with SD, and no patients with progressive disease; median PFS was 16.7 months. Patients with an early CgA or NSE response had a longer PFS compared with patients without an early response. Coadministration of octreotide LAR and everolimus did not impact exposure to either drug. Most adverse events were mild to moderate and were consistent with those previously seen with everolimus. Conclusion Daily everolimus, with or without concomitant octreotide LAR, demonstrates antitumor activity as measured by objective response rate and PFS and is well tolerated in patients with advanced pancreatic NETs after failure of prior systemic chemotherapy.
Medical records documentation of constipation preceding Parkinson disease
Savica, Rodolfo , Carlin, J. M., Grossardt, Brandon R. , Bower, James H., Ahlskog, J. Eric , Maraganore, Demetrius M. , Bharucha, Adil E. , Rocca, Walter A. , Grossardt, Brandon R

Mayo Clinic

Neurology | November 23, 2009 | Volume: 73 | Issue: 21 | Pages: 1752-1758

10.1212/wnl.0b013e3181c34af5 | PMID 19933976 Get It

Comparison of Three Whole Blood Creatinine Methods for Estimation of Glomerular Filtration Rate Before Radiographic Contrast Administration
Korpi‐Steiner, Nichole , Williamson, Eric E. , Karon, Brad S.

Mayo Clinic

American Journal of Clinical Pathology | November 19, 2009 | Volume: 132 | Issue: 6 | Pages: 920-926

10.1309/ajcpte5fey0vcgoz | PMID 19926585 Get It

Abstract We compared the clinical concordance of estimated glomerular filtration rate (eGFR) based on 3 whole blood creatinine assays with the eGFR calculated from a reference plasma creatinine assay. Whole blood creatinine on the Radiometer ABL800 FLEX (Radiometer A/S, Bronshoj, Denmark) demonstrated the best correlation and concordance to plasma creatinine/eGFR compared with the i-STAT (i-STAT, East Windsor, NJ) and StatSensor (Nova Biomedical, Waltham, MA). The i-STAT had better sensitivity (compared with Radiometer) but poorer specificity for prediction of plasma eGFR less than 60 mL/min/1.73 m2. The StatSensor demonstrated lower concordance of whole blood to plasma eGFR but offered a slope and an intercept offset feature that partially compensates for this effect. The optimal device for use in rapid determination of eGFR from whole blood creatinine may depend on whether it is more important in a given practice to optimize sensitivity, specificity, or overall concordance for determining plasma eGFR less than 60 mL/min/1.73 m2.
Toxicity of Bisphosphonates
Prommer, Eric

Mayo Clinic

Journal of Palliative Medicine | November 18, 2009 | Volume: 12 | Issue: 11 | Pages: 1061-1065

10.1089/jpm.2009.9936 | PMID 19922007 Get It

Impact of Abdominal Obesity on Incidence of Adverse Metabolic Effects Associated With Antihypertensive Medications
Wen, Sheron, Beitelshees, Amber L. , Zineh, Issam, Gums, John G. , Hall, Karen , Parekh, Vishal, Chapman, Arlene B. , Boerwinkle, Eric , Johnson, Julie A. , Beitelshees, Amber L. , Cooper‐DeHoff, Rhonda M. , Turner, Stephen T. , Gong, Yan , Chapman, Arlene B.

Mayo Clinic

Hypertension | November 17, 2009 | Volume: 55 | Issue: 1 | Pages: 61-68

10.1161/hypertensionaha.109.139592 | PMID 19917874 Get It

We assessed adverse metabolic effects of atenolol and hydrochlorothiazide among hypertensive patients with and without abdominal obesity using data from a randomized, open-label study of hypertensive patients without evidence of cardiovascular disease or diabetes mellitus. Intervention included randomization to 25 mg of hydrochlorothiazide or 100 mg of atenolol monotherapy followed by their combination. Fasting glucose, insulin, triglycerides, high-density lipoprotein cholesterol, and uric acid levels were measured at baseline and after monotherapy and combination therapy. Outcomes included new occurrence of and predictors for new cases of glucose ≥100 mg/dL (impaired fasting glucose), triglyceride ≥150 mg/dL, high-density lipoprotein ≤40 mg/dL for men or ≤50 mg/dL for women, or new-onset diabetes mellitus according to the presence or absence of abdominal obesity. Abdominal obesity was present in 167 (58%) of 395 patients. Regardless of strategy, in those with abdominal obesity, 20% had impaired fasting glucose at baseline compared with 40% at the end of study ( P <0.0001). Proportion with triglycerides ≥150 mg/dL increased from 33% at baseline to 46% at the end of study ( P <0.01). New-onset diabetes mellitus occurred in 13 patients (6%) with and in 4 patients (2%) without abdominal obesity. Baseline levels of glucose, triglyceride, and high-density lipoprotein predicted adverse outcomes, and predictors for new-onset diabetes mellitus after monotherapy in those with abdominal obesity included hydrochlorothiazide strategy (odds ratio: 46.91 [95% CI: 2.55 to 862.40]), female sex (odds ratio: 31.37 [95% CI: 2.10 to 468.99]), and uric acid (odds ratio: 3.19 [95% CI: 1.35 to 7.52]). Development of adverse metabolic effect, including new-onset diabetes mellitus associated with short-term exposure to hydrochlorothiazide and atenolol was more common in those with abdominal obesity.
Percutaneous Nephrolithotomy for Large or Multiple Upper Tract Calculi and Autosomal Dominant Polycystic Kidney Disease
Umbreit, Eric , Childs, M. Adam, Patterson, David E., Torres, Vicente E. , LeRoy, Andrew J., Gettman, Matthew T., Torres, Vicente E

Mayo Clinic

Journal of Urology | November 14, 2009 | Volume: 183 | Issue: 1 | Pages: 183-187

10.1016/j.juro.2009.08.141 | PMID 19913818 Get It

The Ethics of Rationing of Critical Care Services: Should Technology Assessment Play a Role?
Bloomfield, Eric L.

Mayo Clinic

Anesthesiology Research and Practice | November 11, 2009 | Volume: 2009 | Issue: No issue available | Pages: 1-8

10.1155/2009/915197 | PMID 20798878 Get It

The costs of health care continue to increase rapidly and steeply in the United States. One area of great expense is that of intensive care units (ICUs). The causes of inflation have not been addressed effectively. ICU resources could become stretched such that they may no longer be available. This paper discusses some of the ethics and concerns behind decision making when providing ICU services in the United States. In particular, the use of electronic records with decision making tools, risk-analysis methods, and documentation of patient wishes for extraordinary care may help with better utilization of resources in the future.